Stock LAB B GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
Add to a list
To use this feature you must be a member
Log inSign up

Company Genomma Lab Internacional, S.A.B. de C.V.

Equities

LAB B

MX01LA010006

Pharmaceuticals

End-of-day quote Mexican S.E.
Other stock markets
 06:00:00 2024-07-08 pm EDT 		5-day change 1st Jan Change
18.25 MXN +2.93% Intraday chart for Genomma Lab Internacional, S.A.B. de C.V. +11.14% +28.88%
Jul. 08 Mexican Stocks Reverse Two-Session Losing Streak DJ
Jun. 27 Tranche Update on Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B)'s Equity Buyback Plan announced on March 20, 2013. CI

Business Summary

Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.

Number of employees: 1,590

Sales per Business

MXN in Million2022Weight2023Weight Delta
Pharmaceutical Products and Personal Care Products
100.0 %
16,820 100.0 % 16,467 100.0 % -2.10%

Sales per region

MXN in Million2022Weight2023Weight Delta
International
51.2 %
10,069 59.9 % 8,431 51.2 % -16.27%
Mexico
48.8 %
6,751 40.1 % 8,037 48.8 % +19.05%

Managers

Managers TitleAgeSince
Marco Sparvieri CEO
 Chief Executive Officer - -
Rodrigo Alonso Herrera Aspra FOU
 Founder - 96-10-29
Antonio Zamora Galland DFI
 Director of Finance/CFO - -
Jorge Luis Brake Valderrama BRD
 Director/Board Member - 18-09-09
Marco Francisco Forastieri Muñoz BRD
 Director/Board Member - 12-03-28
Alejandro Bastón Patiño IRO
 Public Communications Contact - 08-09-30

Members of the board

Members of the board TitleAgeSince
Burkhard Wittek BRD
 Director/Board Member 70 18-04-17
Juan Carlos Gavito Aspe BRD
 Director/Board Member - -
Rodrigo Alonso Herrera Aspra FOU
 Founder - 96-10-29
Sabrina Lucila Herrera Aspra BRD
 Director/Board Member - 97-12-31
Jorge Ricardo Gutiérrez Muñoz BRD
 Director/Board Member 80 -
Marco Francisco Forastieri Muñoz BRD
 Director/Board Member - 12-03-28
Jorge Luis Brake Valderrama BRD
 Director/Board Member - 18-09-09
Carlos Javier Vara Alonso BRD
 Director/Board Member - 18-04-17
Javier Vale Castilla BRD
 Director/Board Member - -
Ignacio Gonzalez Rodriguez BRD
 Director/Board Member - -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,020,000,000 710,124,000 ( 69.62 %) 74,855,920 ( 7.339 %) 69.62 %

Shareholders

NameEquities%Valuation
Rodrigo Alonso Herrera Aspra
30.38 %
309,876,000 30.38 % 292 M $
Skagen AS (Investment Management)
2.451 %
25,000,471 2.451 % 24 M $
MFS International (UK) Ltd.
1.721 %
17,549,744 1.721 % 17 M $
Lemanik Asset Management SA
1.555 %
15,863,042 1.555 % 15 M $
Operadora de Fondos Banorte SA de CV
1.085 %
11,068,100 1.085 % 10 M $
North of South Capital LLP
1.021 %
10,418,796 1.021 % 10 M $
Sabrina Lucila Herrera Aspra
1.000 %
10,200,000 1.000 % 10 M $
Marco Francisco Forastieri Muñoz
0.9375 %
9,562,500 0.9375 % 9 M $
BlackRock México Operadora SA de CV SOFI
0.9292 %
9,478,136 0.9292 % 9 M $
Sanlam Investment Management (Pty) Ltd.
0.7845 %
8,002,119 0.7845 % 8 M $

Company contact information

Genomma Lab Internacional SAB de CV

Avendia Antonio Dovalí Jaime, 70 Torre C, Piso 2, Despacho A

01210, Mexico City

+

http://www.genommalab.com
address Genomma Lab Internacional, S.A.B. de C.V.(LAB B)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Ratings for Genomma Lab Internacional, S.A.B. de C.V.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
18.25 MXN
Average target price
19.67 MXN
Spread / Average Target
+7.76%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. Stock Genomma Lab Internacional, S.A.B. de C.V.
+28.88% 960M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+59.97% 840B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+38.38% 621B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.18% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.61% 319B
ABBVIE INC. Stock AbbVie Inc.
+8.44% 297B
ASTRAZENECA PLC Stock AstraZeneca PLC
+12.68% 237B
NOVARTIS AG Stock Novartis AG
+14.40% 221B
ROCHE HOLDING AG Stock Roche Holding AG
+0.04% 220B
AMGEN INC. Stock Amgen Inc.
+9.68% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LAB B Stock
  4. Company Genomma Lab Internacional, S.A.B. de C.V.